Equinext
Lexington
About Equinext
Equinext, LLC develops technologies for the treatment of ligament and tendon injuries in horses in the United States. It offers nonsurgical exogenous crosslink therapy (NEXT), a chemically made device formed following injection of a crosslinking agent into the lesion of the tendon or ligament that interacts with the native proteins (collagen). The company’s products are also used to treat the causes of wobbler’s disease and intervertebral disc degradation. It has strategic partnership with Hagyard Equine Medical Institute. The company was incorporated in 2011 and is based in Lexington, Kentucky.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $985.0K
- Funding stage: Seed
- Last round: Seed (Dec 2013)
- Website: equinext.net
- Phone: 866.348.1991
Industries & Categories
Hardware
Social Profiles
Canonical: https://fsome.com/organization/equinext-2046832 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.